Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL®, and new data ...

A global Phase III study in venous leg ulcers (VLUs) is currently underway, with a Phase II/III study in diabetic foot ulcers (DFUs) in preparation. EscharEx has shown clinical advantages over the ...

Diabetes is a lifelong condition whose consequences can be varied: nerve damage, heart disease, digestive problems, foot ulcers ... a feat of logistical and scientific endurance.

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 FibroBiologics, Inc. (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 ...

Our Phase 1/2a clinical trial has demonstrated that the use of this stem cell population in humans is safe and effective in treating hard to heal diabetic foot ulcers ... who is also the scientific ...

In March, Croatian pharmaceutical company Pliva (Zagreb) invested $14.4 million in the venture, which has as its scientific ... infections of diabetic foot ulcers. Trial results demonstrated ...

Discover the foot care oversights people with type 2 diabetes make and learn simple preventive strategies to protect ...

Caring for people with diabetic foot ulcers costs NHS England the region of £1 billion a year, but the developer of a new digital tool says it could help reduce the burden.

A podiatrist cannot diagnose diabetes, but they can look for signs of diabetic neuropathy, such as nerve damage, circulation ...

In the last 20 years, the goals of diabetic foot surgery have changed substantially and are now considered an integral part of successful management of the neuropathic ulcer. Surgical procedures ...

Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care managementThree ...